In vivo response-based identification of direct hormone target cell populations using high-density tissue arrays.
To identify cell populations directly responsive to prolactin (PRL), GH, erythropoietin, or granulocyte-colony stimulating factor within the physiological setting of an intact mammal, we combined in situ detection of hormone-activated signal transducer and activator of transcription (Stat)-5 in rats with high-throughput tissue array analysis using cutting-edge matrix assembly (CEMA). Inducible activation of Stat5a/b, as judged by levels of nuclear-localized, phosphoTyr694/699-Stat5a/b, served as an immediate and sensitive in situ marker of receptor signaling in rat tissues after injection into male and female rats of a single, receptor-saturating dose of hormone for maximal receptor activation. CEMA tissue arrays facilitated analysis of most tissues, including architecturally complex, thin-walled, and stratified tissues such as gut and skin. In 40 tissues analyzed, 35 PRL-responsive and 32 GH-responsive cell types were detected, of which 22 cell types were responsive to both hormones. Interestingly, PRL but not GH activated Stat5 in nearly all of the endocrine glands. In mammary glands, PRL activated Stat5 in a majority of luminal epithelial cells but not myoepithelial cells, stromal fibroblasts, or adipocytes, whereas GH activated Stat5 in a significant fraction of myoepithelial cells, fibroblasts, and adipocytes but only in a minority of luminal cells. Finally, the organism-wide screening revealed a yet-to-be identified erythropoietin-responsive cell type in connective tissue. CEMA tissue arrays provide cost-effective in situ analysis of large numbers of tissues. Biomarker-based identification of cell populations responsive to individual hormones may shed new light on endocrine disease as well as improve understanding of effects and side effects of hormones and drugs.
LeBaron
M J
MJ
Thomas Jefferson University, Kimmel Cancer Center, Department of Cancer Biology, 233 South 10th Street, 330 BLSB, Philadelphia, PA 19107-5541, USA. mlebaron@kimmelcancercenter.org
Ahonen
T J
TJ
Nevalainen
M T
MT
Rui
H
H
D000818:Animals; D004702:Endocrine Glands / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D006066:Gonads / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D013006:Growth Hormone / Q000494:pharmacology*; D017403:In Situ Hybridization; D007515:Islets of Langerhans / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009928:Organ Specificity / Q000187:drug effects; D011388:Prolactin / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D050799:STAT5 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D046888:Tissue Array Analysis
D050799:STAT5 Transcription Factor; C494094:Stat5a protein, rat; D004921:Erythropoietin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D011388:Prolactin; D013006:Growth Hormone